Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Metzgeroth

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Leukemia|October 5, 2007
The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locusS Burgstaller, S Kreil, K Waghorn, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|July 29, 2017
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophiliaM Jawhar, N Naumann, M Knut, et al.
Leukemia|March 23, 2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphomaG Metzgeroth, C Walz, J Score, et al.
Leukemia|May 3, 2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)M Mossner, J-C Jann, D Nowak, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Leukemia|October 5, 2007
The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locusS Burgstaller, S Kreil, K Waghorn, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|July 16, 2016
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosisM Jawhar, J Schwaab, D Hausmann, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia|January 9, 2015
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late eventM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Leukemia|July 29, 2017
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophiliaM Jawhar, N Naumann, M Knut, et al.
Leukemia|March 23, 2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphomaG Metzgeroth, C Walz, J Score, et al.
Leukemia|May 3, 2016
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)M Mossner, J-C Jann, D Nowak, et al.
Leukemia|July 30, 2003
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyureaR Hehlmann, U Berger, M Pfirrmann, et al.
Pageof 2